SurModics Inc. (NASDAQ:SRDX) CEO Gary R. Maharaj sold 5,000 shares of the company’s stock in a transaction on Monday, October 3rd. The stock was sold at an average price of $29.55, for a total transaction of $147,750.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Shares of SurModics Inc. (NASDAQ:SRDX) opened at 29.23 on Friday. The company has a 50 day moving average of $29.04 and a 200-day moving average of $24.48. The stock has a market cap of $381.31 million, a price-to-earnings ratio of 43.69 and a beta of 0.97. SurModics Inc. has a one year low of $17.45 and a one year high of $30.75.
SurModics (NASDAQ:SRDX) last posted its quarterly earnings data on Thursday, July 28th. The company reported $0.37 earnings per share for the quarter, beating analysts’ consensus estimates of $0.12 by $0.25. SurModics had a net margin of 14.45% and a return on equity of 17.11%. The firm had revenue of $19.97 million for the quarter, compared to analyst estimates of $16.31 million. During the same period last year, the firm posted $0.30 EPS. SurModics’s quarterly revenue was up 25.6% on a year-over-year basis. On average, analysts anticipate that SurModics Inc. will post $1.04 earnings per share for the current year.
Institutional investors have recently bought and sold shares of the stock. Prudential Financial Inc. raised its position in SurModics by 0.9% in the first quarter. Prudential Financial Inc. now owns 46,162 shares of the company’s stock worth $850,000 after buying an additional 400 shares during the period. BlackRock Group LTD raised its position in SurModics by 5.8% in the second quarter. BlackRock Group LTD now owns 16,841 shares of the company’s stock worth $395,000 after buying an additional 930 shares during the period. Principal Financial Group Inc. raised its position in SurModics by 2.9% in the second quarter. Principal Financial Group Inc. now owns 91,696 shares of the company’s stock worth $2,153,000 after buying an additional 2,580 shares during the period. Gabelli Funds LLC raised its position in SurModics by 2.4% in the second quarter. Gabelli Funds LLC now owns 128,626 shares of the company’s stock worth $3,020,000 after buying an additional 3,000 shares during the period. Finally, Metropolitan Life Insurance Co. NY raised its position in SurModics by 44.7% in the first quarter. Metropolitan Life Insurance Co. NY now owns 12,386 shares of the company’s stock worth $228,000 after buying an additional 3,824 shares during the period. Hedge funds and other institutional investors own 86.42% of the company’s stock.
A number of brokerages have recently commented on SRDX. Sidoti cut shares of SurModics from a “buy” rating to a “neutral” rating in a research report on Thursday. Zacks Investment Research cut shares of SurModics from a “buy” rating to a “hold” rating in a research report on Tuesday, July 5th.
SurModics Company Profile
SurModics, Inc is a provider of surface modification and in vitro diagnostic technologies to the healthcare industry. The Company operates through two segments: Medical Device and In Vitro Diagnostics. The Company is focused on to transform its medical device business from being a provider of coating technologies to offering whole product solutions to medical device customers.
Receive News & Ratings for SurModics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SurModics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.